Plus Therapeutics Inc (PSTV)

May 08, 2025

Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference - GlobeNewswire

May 08, 2025

May 07, 2025

Plus Therapeutics (NASDAQ:PSTV) Stock Rating Lowered by D Boral Capital - Defense World

May 07, 2025

May 06, 2025

Plus Therapeutics (NASDAQ:PSTV) Given Hold Rating at D. Boral Capital - Defense World

May 06, 2025

May 05, 2025

Plus Therapeutics (PSTV) Downgraded Amid Planned Reverse Stock S - GuruFocus

May 05, 2025

May 05, 2025

Colorectal Cancer Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa - Barchart.com

May 05, 2025

May 05, 2025

This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga

May 05, 2025

May 05, 2025

Plus Therapeutics (PSTV) Receives Downgrade to Hold by D. Boral Capital | PSTV Stock News - GuruFocus

May 05, 2025

May 02, 2025

PSTV Stock Sees Decline of Approximately -22.86% in Last Five Days - knoxdaily.com

May 02, 2025

May 02, 2025

Form 8-KCurrent report - ADVFN

May 02, 2025

Apr 30, 2025

Plus Therapeutics Inc (PSTV) can make a big difference with a little luck - Sete News

Apr 30, 2025

Apr 29, 2025

Investing in Plus Therapeutics Inc (PSTV): What You Must Know - knoxdaily.com

Apr 29, 2025

Apr 28, 2025

Plus Therapeutics Inc: A Comprehensive Look at the Stock’s Ups and Downs - investchronicle.com

Apr 28, 2025

Apr 28, 2025

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors - The Houston 100

Apr 28, 2025

Apr 24, 2025

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - ADVFN

Apr 24, 2025

Apr 24, 2025

Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Zacks Investment Research

Apr 24, 2025

Apr 23, 2025

Plus Therapeutics adds Kyle Guse to its Board of Directors By Investing.com - Investing.com South Africa

Apr 23, 2025

Apr 23, 2025

Plus Therapeutics Inc (PSTV) may enjoy gains as insiders got busy in the recent days - knoxdaily.com

Apr 23, 2025

Apr 23, 2025

Plus Therapeutics adds Kyle Guse to its Board of Directors - Investing.com

Apr 23, 2025

Apr 23, 2025

Plus Therapeutics (PSTV) Welcomes Kyle Guse to Board as Audit Ch - GuruFocus

Apr 23, 2025

Apr 23, 2025

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins Its Board Of Directors - marketscreener.com

Apr 23, 2025

Apr 23, 2025

Plus Therapeutics Strengthens Board: Former Atossa CFO Brings 30 Years of NYSE and NASDAQ Leadership - Stock Titan

Apr 23, 2025

Apr 22, 2025

Plus Therapeutics (NASDAQ:PSTV) Price Target Raised to $20.00 at Ascendiant Capital Markets - Defense World

Apr 22, 2025

Apr 21, 2025

Short Interest in Plus Therapeutics, Inc. (NASDAQ:PSTV) Rises By 34.5% - Defense World

Apr 21, 2025

Apr 19, 2025

Plus Therapeutics Appoints Kyle Guse to Board - MSN

Apr 19, 2025

Apr 15, 2025

Plus Therapeutics reports progress in CNS cancer treatment By Investing.com - Investing.com Canada

Apr 15, 2025

Apr 15, 2025

Plus Therapeutics Inc (NASDAQ: PSTV) Analysts Expect It Could Climb 89.63% From Current Levels. - stocksregister.com

Apr 15, 2025

Apr 15, 2025

Plus Therapeutics Presents New Data Highlighting Clinical Benefi - GuruFocus

Apr 15, 2025

Apr 15, 2025

Plus Therapeutics (PSTV) Unveils Promising Data on REYOBIQ at Upcoming Conference | PSTV Stock News - GuruFocus

Apr 15, 2025

Apr 15, 2025

Plus Therapeutics reports progress in CNS cancer treatment - Investing.com

Apr 15, 2025

Apr 15, 2025

Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases - The Manila Times

Apr 15, 2025

Apr 15, 2025

Plus Therapeutics Presents New Data Highlighting Clinical - GlobeNewswire

Apr 15, 2025

Apr 15, 2025

New Cancer Drug REYOBIQ Achieves Breakthrough 86% Clinical Benefit in Brain Metastases Study - Stock Titan

Apr 15, 2025

Apr 04, 2025

Plus Therapeutics (PSTV) Plans Massive Stock Sale - GuruFocus

Apr 04, 2025

Apr 04, 2025

Plus Therapeutics Inc (PSTV) Volatility Hits 17.12% – Here Is What You Should Do - Stocksregister

Apr 04, 2025

Apr 01, 2025

Promising Outlook for Plus Therapeutics: Buy Rating Affirmed Amid Clinical and Financial Advancements - TipRanks

Apr 01, 2025

Apr 01, 2025

Plus Therapeutics: What’s Fueling the Surge? - timothysykes.com

Apr 01, 2025

Mar 31, 2025

PLUS THERAPEUTICS Inc. (PSTV) reports earnings - Quartz

Mar 31, 2025

Mar 31, 2025

12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga

Mar 31, 2025

Mar 31, 2025

What is HC Wainwright’s Estimate for PSTV FY2029 Earnings? - Defense World

Mar 31, 2025

Mar 30, 2025

HC Wainwright Has Lowered Expectations for Plus Therapeutics (NASDAQ:PSTV) Stock Price - Defense World

Mar 30, 2025

Mar 29, 2025

Plus Therapeutics outlines REYOBIQ expansion plans and CNSide launch timeline - MSN

Mar 29, 2025

Mar 29, 2025

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer - AOL

Mar 29, 2025

Mar 28, 2025

Earnings call transcript: Plus Therapeutics’ Q4 2024 results highlight innovation - Investing.com Australia

Mar 28, 2025

Mar 28, 2025

H.C. Wainwright cuts Plus Therapeutics price target to $5.50 - Investing.com Australia

Mar 28, 2025

Mar 28, 2025

H.C. Wainwright cuts Plus Therapeutics price target to $5.50 By Investing.com - Investing.com Canada

Mar 28, 2025